Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
about
Characterization of model peptide adducts with reactive metabolites of naphthalene by mass spectrometryReal-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing.Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.Profiling the reactive metabolites of xenobiotics using metabolomic technologiesIrreversible binding of an anticancer compound (BI-94) to plasma proteins.Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity.The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.Practical approaches to resolving reactive metabolite liabilities in early discovery.Non-cytochrome P450-mediated bioactivation and its toxicological relevance.HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.Development of a profiling strategy for metabolic mixtures by combining chromatography and mass spectrometry with cell-based GPCR signaling.Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes.
P2860
Q28482068-1148E333-D4C6-4E5F-B8E1-697DE37CE7A8Q33804664-52E3AA71-3AF9-4CCF-8AF8-EC2E0259819AQ34181630-44A18495-56E4-415C-86F2-55A7AB464D9DQ34702576-435F8872-988B-43DB-86C9-D01F22493A6AQ35001524-5477599D-BF6B-4D26-A79B-B78709B9FB0BQ36005906-5ECE21F8-DBE5-47F1-8976-7B24EE46739DQ36951911-AF408E38-7A73-4B95-9F8D-EF350D6F6FECQ37550673-07386826-BD4E-41F7-B76F-C9F03D2D65C7Q37950014-B72B7E85-606D-4B75-929C-525F3313C6B0Q37979858-F42C108B-BD1D-4924-A0E4-D3FA3EEBAB9CQ38218540-AE2B67B9-706C-4690-A366-EF6E3827101BQ38269781-3BFEA8FC-ABCE-45A0-9430-76F0EB4DB9D7Q38929936-8DFE2D12-B8B4-4546-8CBF-706AA9A23126Q39196823-F6D9C6C7-A009-495C-8434-62908E203EA2Q39323929-079B8BD9-66BE-418A-A4FB-8541E88C0F33Q47951975-A309E1BD-8CD3-4B86-9E9D-6E1FA647A35C
P2860
Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolic bioactivation and dr ...... ceutical research perspective.
@en
Metabolic bioactivation and dr ...... ceutical research perspective.
@nl
type
label
Metabolic bioactivation and dr ...... ceutical research perspective.
@en
Metabolic bioactivation and dr ...... ceutical research perspective.
@nl
prefLabel
Metabolic bioactivation and dr ...... ceutical research perspective.
@en
Metabolic bioactivation and dr ...... ceutical research perspective.
@nl
P2860
P1476
Metabolic bioactivation and dr ...... ceutical research perspective.
@en
P2093
Anthony Y H Lu
P2860
P304
P356
10.3109/03602530903401658
P407
P577
2010-05-01T00:00:00Z